BioNTech, the German developer of a widely used mRNA vaccine for the coronavirus, agreed to pay US$800 million (HK$6.24 ...

Analysts have set 12-month price targets for BioNTech, revealing an average target of $132.24, a high estimate of $171.00, ...

In 2021, with the COVID-19 pandemic in full swing, BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) were the darlings of the pharma and biotech worlds. The two mRNA therapy developers created ...

Moderna – at the moment embroiled in a patent dispute with Pfizer and BioNTech over mRNA intellectual property – is also testing a vaccine that combines COVID-19 and flu in a single jab in a ...

BioNTech, founded in 2008 in Germany, has become a key player in the development of personalized mRNA cancer treatments. The emerging biotech's first commercial vaccine, for covid, received its ...

German drugmaker BioNTech on Monday lowered its guidance for full-year revenue, citing COVID-19 uptake and price levels, ...

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

On Aug. 22, the Food and Drug Administration approved and authorized newer formulations of the two mRNA vaccines, from Pfizer ...

BioNTech’s top line currently includes sales from its mRNA-based COVID-19 vaccine, Comirnaty, developed in partnership with Pfizer PFE. The vaccine is approved in several countries and has been ...

COVID-19 – Influenza Combination Vaccine Program An mRNA-based combination vaccine candidate (BNT162b2 + BNT161) against COVID-19 and influenza is in development in collaboration with Pfizer. In ...

In August 2024, BioNTech and Pfizer provided topline results from the Phase 3 trial (NCT06178991) evaluating the companies’ mRNA combination vaccine candidate in healthy individuals 18-64 ...